Sildenafil’s protective effect against cardiac hypertrophy

References

• Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am. Heart J.141, 334–341 (2001).
   PubMed Web of Science ®Google Scholar
• McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov.6, 617–635 (2007).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am. J. Hypertens.21, 500–508 (2008).
   PubMed Web of Science ®Google Scholar
• Hill JA, Olson EN. Cardiac plasticity. N. Engl. J. Med.358, 1370–1380 (2008).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation116, 700–705 (2007).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA292, 2343–2349 (2004).
   PubMed Web of Science ®Google Scholar
• Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol.65, 45–79 (2003).
   PubMed Web of Science ®Google Scholar
• Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol.7, 589–600 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther.122, 216–238 (2009).
   PubMed Web of Science ®Google Scholar
• Surks HK. cGMP-dependent protein kinase I and smooth muscle relaxation: a tale of two isoforms. Circ. Res.101, 1078–1080 (2007).
   PubMedGoogle Scholar
• Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest.101, 812–818 (1998).
   PubMed Web of Science ®Google Scholar
• Holtwick R, van Eickels M, Skryabin BV et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J. Clin. Invest.111, 1399–1407 (2003).
   PubMed Web of Science ®Google Scholar
• Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl Acad. Sci. USA98, 2703–2706 (2001).
   PubMed Web of Science ®Google Scholar
• Knowles JW, Esposito G, Mao L et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest.107, 975–984 (2001).
   PubMed Web of Science ®Google Scholar
• Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J. Biol. Chem.278, 47694–47699 (2003).
   PubMed Web of Science ®Google Scholar
• Takimoto E, Champion HC, Li M et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med.11, 214–222 (2005).
   PubMed Web of Science ®Google Scholar
• Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res.101, 1084–1095 (2007).
   PubMed Web of Science ®Google Scholar
• Kukreja RC, Salloum F, Das A et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul. Pharmacol.42, 219–232 (2005).
   PubMed Web of Science ®Google Scholar
• Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol. Heart Circ. Physiol.283, H1263–H1269 (2002).
   PubMed Web of Science ®Google Scholar
• Perez NG, Piaggio MR, Ennis IL et al. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension49, 1095–1103 (2007).
   PubMed Web of Science ®Google Scholar
• Salloum FN, Abbate A, Das A et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am. J. Physiol. Heart Circ. Physiol.294, H1398–H1406 (2008).
   PubMed Web of Science ®Google Scholar
• Omori K, Kotera J. Overview of PDEs and their regulation. Circ. Res.100, 309–327 (2007).
   PubMed Web of Science ®Google Scholar
• Takimoto E, Champion HC, Belardi D et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ. Res.96, 100–109 (2005).
   PubMed Web of Science ®Google Scholar
• Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation112, 2642–2649 (2005).
   PubMed Web of Science ®Google Scholar
• Senzaki H, Smith CJ, Juang GJ et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J.15, 1718–1726 (2001).
   PubMed Web of Science ®Google Scholar
• Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J. Pharmacol. Exp. Ther.326, 380–387 (2008).
   PubMed Web of Science ®Google Scholar
• Takimoto E, Belardi D, Tocchetti CG et al. Compartmentalization of cardiac β-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation115, 2159–2167 (2007).
   PubMed Web of Science ®Google Scholar
• Nagendran J, Archer SL, Soliman D et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation116, 238–248 (2007).
   PubMed Web of Science ®Google Scholar
• Pokreisz P, Vandenwijngaert S, Bito V et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation119, 408–416 (2009).
   PubMed Web of Science ®Google Scholar
• Nagayama T, Hsu S, Zhang M et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J. Am. Coll. Cardiol.53, 207–215 (2009).
   PubMed Web of Science ®Google Scholar
• Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol.572, 12–22 (2007).
   PubMed Web of Science ®Google Scholar
• Redondo J, Bishop JE, Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br. J. Pharmacol.124, 1455–1462 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang M, Koitabashi N, Nagayama T et al. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell. Signal.20, 2231–2236 (2008).
   PubMed Web of Science ®Google Scholar
• Das A, Xi L, Kukreja RC. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3β. J. Biol. Chem.283, 29572–29585 (2008).
   PubMed Web of Science ®Google Scholar
• Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am. J. Physiol. Heart Circ. Physiol.296, H1236–H1243 (2009).
   PubMed Web of Science ®Google Scholar
• Khairallah M, Khairallah RJ, Young ME et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc. Natl Acad. Sci. USA105, 7028–7033 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis GD, Shah R, Shahzad K et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation116, 1555–1562 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis GD, Lachmann J, Camuso J et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation115, 59–66 (2007).
   PubMed Web of Science ®Google Scholar
• Yang L, Liu G, Zakharov SI, Bellinger AM, Mongillo M, Marx SO. Protein kinase G phosphorylates Cav1.2 α1c and β2 subunits. Circ. Res.101, 465–474 (2007).
   PubMed Web of Science ®Google Scholar
• Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc. Res.66, 12–21 (2005).
   PubMed Web of Science ®Google Scholar
• Kruger M, Kotter S, Grutzner A et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res.104, 87–94 (2009).
   PubMed Web of Science ®Google Scholar
• Tang KM, Wang GR, Lu P et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat. Med.9, 1506–1512 (2003).
   PubMed Web of Science ®Google Scholar
• Tokudome T, Kishimoto I, Horio T et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation117, 2329–2339 (2008).
   PubMed Web of Science ®Google Scholar
• Fiedler B, Lohmann SM, Smolenski A et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc. Natl Acad. Sci. USA99, 11363–11368 (2002).
   PubMed Web of Science ®Google Scholar
• Hsu S, Nagayama T, Koitabashi N et al. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc. Res.81, 301–309 (2009).
   PubMed Web of Science ®Google Scholar
• Takimoto E, Koitabashi N, Hsu S et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest.119, 408–420 (2009).
   PubMedGoogle Scholar
• Nagayama T, Hsu S, Zhang M et al. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J. Mol. Cell. Cardiol.46, 560–567 (2009).
   PubMedGoogle Scholar
• Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J. Clin. Invest.115, 518–526 (2005).
   PubMed Web of Science ®Google Scholar
• Croom KF, Curran MP, Abman SH et al. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs68, 383–397 (2008).
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.353, 2148–2157 (2005).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Kreisselmeier KP, Ghofrani HA et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med.169, 39–45 (2004).
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Paul GA, Strange JW et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med.171, 1292–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Schäfer S, Ellinghaus P, Janssen W et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc. Res.82, 30–39 (2009).
   PubMedGoogle Scholar
• Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur. J. Heart Fail.10, 1158–1165 (2008).
   PubMedGoogle Scholar